A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5
days (Treatment A) followed by a washout period. In Period 2, subjects will receive
GSK2248761 200mg once daily for 5 days (Treatment B). There will be no wash out between
Period 2 and 3. Subjects will then be administered raltegravir 400mg twice daily in
combination with GSK2248761 200mg once daily (Treatment C) for 5 days. Subjects will be
housed in the unit for the duration of the study. Safety evaluations and serial PK samples
will be collected during each treatment period. A follow-up visit will occur 7-14 days after
the last dose of study drug.